Regeneron Pharmaceuticals, Inc. has announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited to acquire exclusive clinical development and commercial rights for a dual GLP-1/GIP receptor agonist, HS-20094, outside of the Chinese Mainland, Hong Kong, and Macau. Currently in Phase 3 testing, this therapeutic candidate has been studied in over 1,000 patients as a weekly subcutaneous injection, showing promising efficacy and safety data. The agreement includes an upfront payment of $80 million to Hansoh, with potential additional payments up to $1.93 billion based on achievement of development, regulatory, and sales milestones. Regeneron aims to integrate this candidate into its portfolio to address muscle loss and other obesity-related comorbidities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.